Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?

OptimizeRx nears Q1 earnings amid declining revenue forecasts, softer trends and a cautious outlook, raising questions on near-term upside.

Zacks Investment Research • 7 hours ago

3 Medical Info Systems Stocks Riding the GenAI Wave in a Tough Market

Doximity, Veeva and Omnicell ride surging GenAI adoption in healthcare, tapping digital demand despite market pressure and rising cybersecurity risks.

Zacks Investment Research • May 4, 2026

Doximity: Buy It As Mr. Market Is Selling It Cheap Under A Panic Attack

Doximity has seen a two-thirds stock price decline, which I attribute mainly to market overreaction and short-term uncertainty, not deteriorating fundamentals. DOCS maintains a robust business model with 90% gross margins, ~30% net margins, strong cash generation, and a dominant network among U.S. healthcare professionals. Recent growth deceleration and vague pharma client budget concerns have pressured the stock, but DOCS remains asset-light with minimal downside risk and ample liquidity.

Seeking Alpha • Apr 28, 2026

Doximity (DOCS) Outperforms Broader Market: What You Need to Know

In the latest trading session, Doximity (DOCS) closed at $24.66, marking a +2.71% move from the previous day.

Zacks Investment Research • Apr 27, 2026

Doximity to Release Fiscal 2026 Fourth Quarter and Full Year Results on May 13, 2026

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal fourth quarter and full year ended March 31, 2026 after market close on May 13, 2026. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximit.

Business Wire • Apr 23, 2026

Wall Street Analysts Think Doximity (DOCS) Is a Good Investment: Is It?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Zacks Investment Research • Apr 23, 2026

Doximity (DOCS) Falls More Steeply Than Broader Market: What Investors Need to Know

Doximity (DOCS) reached $24.39 at the closing of the latest trading day, reflecting a -1.3% change compared to its last close.

Zacks Investment Research • Apr 20, 2026

Harbor Active Small Cap ETF Q1 2026 Portfolio Review

During the first quarter, the Harbor Active Small Cap ETF (“ETF”) returned -4.52% (NAV), significantly underperforming the Russell 2000® Index, which returned 0.89%. Shares are bought and sold at market price not net asset value (NAV). A fund's NAV is the sum of all its assets less any liabilities, divided by the number of shares outstanding. Market price returns are based upon the closing composite market price and do not represent the returns you would receive if you traded shares at other times.

Seeking Alpha • Apr 20, 2026

Doximity (DOCS) Stock Dips While Market Gains: Key Facts

In the closing of the recent trading day, Doximity (DOCS) stood at $22.25, denoting a -1.81% move from the preceding trading day.

Zacks Investment Research • Apr 14, 2026

TEM vs. DOCS: Which Medical Info Systems Stock Is the Better Pick Now?

Tempus AI TEM and Doximity DOCS are two well-established players in the Medical Information Systems industry, each with distinct niche. Tempus is focused on advancing precision medicine through artificial intelligence.

Zacks Investment Research • Mar 31, 2026